IC
AMLX icon

Ikarian Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ikarian Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-186,400
Closed -$529K – 116
2024
Q1 		$529K Buy
+186,400
New +$2.44M 0.06% 117

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ikarian Capital's AMLX Position: Q2 2026 in Review

Ikarian Capital opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 117,500 shares worth $2.11M. The stake represents 0.23% of the portfolio and ranks #88 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in AMLX as recently as Q4 2024.

Ikarian Capital first reported a position in AMLX in Q1 2022 and has held it in 9 quarters since. The position peaked at $12.9M in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Ikarian Capital held 117,500 shares of Amylyx Pharmaceuticals worth $2.11M as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Ikarian Capital position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.23% of Ikarian Capital's portfolio in Q2 2026, its #88 holding.
  • Ikarian Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
  • Ikarian Capital's Amylyx Pharmaceuticals position peaked at $12.9M in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.